The Zhitong Finance App learned that AdarX Pharmaceuticals, an RNA therapy company in the post-clinical development stage, plans to raise up to 371.9 million US dollars through an initial public offering (IPO) in the US. Based on the upper limit of the proposed issue price range, the company's market value after listing is expected to reach approximately US$1.74 billion.

The Zhitong Finance App learned that AdarX Pharmaceuticals, an RNA therapy company in the post-clinical development stage, plans to raise up to 371.9 million US dollars through an initial public offering (IPO) in the US. Based on the upper limit of the proposed issue price range, the company's market value after listing is expected to reach approximately US$1.74 billion.